← Leaderboards
Shiqing Xu
Texas A&M University
$811,129
Attributed
$811,129
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $405.6K · FY2021–23$500K$375K$250K$125K$0
'21
'22
'23
Funding mix
By agency
NIH$811,129 · 2
By mechanism
R21$811,129 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pathogen”
- Scott Hensley · University Of Pennsylvania$49,758,212
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,703,204
- Thomas Denny · Duke University$42,477,454
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Sujatha Rashid · American Type Culture Collection$37,889,194
- Bala Raja · Luminostics, Inc.$28,624,460
Research focus
PathogenPeptide HydrolasesEventMutationInfectionLigand BindingDisadvantagedBindingDrug TargetingLigandsGlobal Health Emergency2019-NcovCessation Of LifeLeadActive SitesCombatComplexCoronavirusBinding SitesCovid-19Covid-19 PandemicDrug DiscoveryCellsPharmaceutical Preparations
Grant awards (4)
Development of PROTACs Targeting Papain-like Protease as Broad-Spectrum Anti-Coronavirus Therapeutics$183,651
R21 · FY2023 · AI · contact PI
Development of PROTACs Targeting Papain-like Protease as Broad-Spectrum Anti-Coronavirus Therapeutics$221,799
R21 · FY2022 · AI · contact PI
The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 Strategy$183,769
R21 · FY2022 · AI · contact PI
The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 Strategy$221,910
R21 · FY2021 · AI · contact PI